EUVIMEDEUVIMED entdecken
Crossref

Brain‐Tumor Interface‐Based MRI Radiomics Models to Determine EGFR Mutation, Response to EGFR‐TKI and T790M Resistance Mutation in Non‐Small Cell Lung Carcinoma Brain Metastasis

Ying Fan, Xinti Wang, Chunna Yang, Huanhuan Chen, Huan Wang, Xiaoyu Wang, Shaoping Hou, Lihua Wang, Yahong Luo iD, Xianzheng Sha, Huazhe Yang, Tao Yu und 1 weitere

Journal of Magnetic Resonance Imaging · 2023-12 · 58 (6) · 1838-1847

DOI: 10.1002/jmri.28751 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Magnetic Resonance Imaging, online erschienen am 05.05.2023. Verfasst von Ying Fan und 12 weiteren Autor:innen. Beteiligte Einrichtung: School of Intelligent Medicine, China Medical University, Shenyang, Liaoning, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Brain Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Fundamental Research Funds for the Central Universities.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Preoperative assessment of epidermal growth factor receptor (EGFR) status, response to EGFR‐tyrosine kinase inhibitors (TKI) and development of T790M mutation in non‐small cell lung carcinoma (NSCLC) patients with brain metastases (BM) is important for clinical decision‐making, while previous studies were only based on the whole BM.

Purpose

To investigate values of brain‐to‐tumor interface (BTI) for determining the EGFR mutation, response to EGFR‐TKI and T790M mutation. Study Type Retrospective. Population Two hundred thirty patients from Hospital 1 (primary cohort) and 80 patients from Hospital 2 (external validation cohort) with BM and histological diagnosis of primary NSCLC, and with known EGFR status (biopsy) and T790M mutation status (gene sequencing). Field Strength/Sequence Contrast‐enhanced T1‐weighted (T1CE) and T2‐weighted (T2W) fast spin echo sequences at 3.0T MRI. Assessment Treatment response to EGFR‐TKI therapy was determined by the Response Evaluation Criteria in Solid Tumors. Radiomics features were extracted from the 4 mm thickness BTI and selected by least shrinkage and selection operator regression. The selected BTI features and volume of peritumoral edema (VPE) were combined to construct models using logistic regression. Statistical Tests The performance of each radiomics model was evaluated using the area under the receiver operating characteristic (ROC) curve (AUC).

Results

A total of 7, 3, and 3 features were strongly associated with the EGFR mutation status, response to EGFR‐TKI and T790M mutation status, respectively. The developed models combining BTI features and VPE can improve the performance than those based on BTI features alone, generating AUCs of 0.814, 0.730, and 0.774 for determining the EGFR mutation, response to EGFR‐TKI and T790M mutation, respectively, in the external validation cohort. Data Conclusion BTI features and VPE were associated with the EGFR mutation status, response to EGFR‐TKI and T790M mutation status in NSCLC patients with BM. Evidence Level: 3 Technical Efficacy: Stage 2

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsBrain NeoplasmsHumansMutationRetrospective StudiesErbB ReceptorsProtein Kinase InhibitorsDrug Resistance, NeoplasmMagnetic Resonance ImagingBrain

Stichwörter der Autor:innen

EGFR-TKIT790Mbrain metastasisbrain-to-tumor interfaceradiomics

Substanzen

ErbB ReceptorsProtein Kinase InhibitorsEGFR protein, human

Autor:innen und Institutionen

  • School of Intelligent Medicine, China Medical University, Shenyang, Liaoning, China.
  • The First Clinical Department of China Medical University, Shenyang, Liaoning, China.
  • Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
  • Radiation Oncology Department of Thoracic Cancer, Liaoning Cancer Hospital and Institute, Shenyang, Liaoning, China.
  • Department of Radiology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, Liaoning, China.

ORCID-Profile: Yahong Luo, Xiran Jiang

Förderung

  • Fundamental Research Funds for the Central Universities

Zitieren

APA

Fan, Y., Wang, X., Yang, C., Chen, H., Wang, H., Wang, X., Hou, S., Wang, L., Luo, Y., Sha, X., Yang, H., Yu, T., & Jiang, X. (2023). Brain‐Tumor Interface‐Based MRI Radiomics Models to Determine EGFR Mutation, Response to EGFR‐TKI and T790M Resistance Mutation in Non‐Small Cell Lung Carcinoma Brain Metastasis. Journal of Magnetic Resonance Imaging, 58(6), 1838-1847. https://doi.org/10.1002/jmri.28751

Vancouver

Fan Y, Wang X, Yang C, Chen H, Wang H, Wang X, et al. Brain‐Tumor Interface‐Based MRI Radiomics Models to Determine EGFR Mutation, Response to EGFR‐TKI and T790M Resistance Mutation in Non‐Small Cell Lung Carcinoma Brain Metastasis. Journal of Magnetic Resonance Imaging. 2023;58(6):1838-1847. doi:10.1002/jmri.28751

BibTeX
@article{Fan2023,
  author = {Fan, Ying and Wang, Xinti and Yang, Chunna and Chen, Huanhuan and Wang, Huan and Wang, Xiaoyu and Hou, Shaoping and Wang, Lihua and Luo, Yahong and Sha, Xianzheng and Yang, Huazhe and Yu, Tao and Jiang, Xiran},
  title = {Brain‐Tumor Interface‐Based MRI Radiomics Models to Determine EGFR Mutation, Response to EGFR‐TKI and T790M Resistance Mutation in Non‐Small Cell Lung Carcinoma Brain Metastasis},
  journal = {Journal of Magnetic Resonance Imaging},
  year = {2023},
  volume = {58},
  number = {6},
  pages = {1838--1847},
  doi = {10.1002/jmri.28751}
}
Kostenlos starten →